2026 Pediatric Rheumatology Symposium

March 18-21, 2026. Minneapolis, MN.

View by Number View by Title View Sessions

Thursday, March 19, 2026

5:29PM-5:34PM: Abstract Number: 042

Mindfulness Matters: Early Insights from the Making Mindfulness Matter© in children with Juvenile Idiopathic Arthritis Study.

Abstracts: Juvenile Idiopathic Arthritis

5:35PM-5:40PM: Abstract Number: 019

Effects of Childhood-Onset Interferon-Driven Autoimmune Disorders on Brain Volume and Executive Function: A Pilot Analysis in JDM and Childhood-Onset SLE

Abstracts: Imaging

5:35PM-5:40PM: Abstract Number: 035

Healthcare and Medication Utilization Before and After JIA diagnosis in Publicly Insured Children in the United States

Abstracts: Juvenile Idiopathic Arthritis

5:35PM-5:40PM: Abstract Number: 012

Prevalence and Impact of Adverse Childhood Experiences in Pediatric Systemic Lupus Erythematosus

Abstracts: Systemic Lupus Erythematosus

6:00PM-7:00PM: Abstract Number: 006

Age Matters: Clinical Profile and IVIG Responsiveness in infants with Kawasaki Disease. A multicentric retrospective analysis of 36 patients from North India

Posters: Clinical and Therapeutic Aspects I

6:00PM-7:00PM: Abstract Number: 040

Antiphospholipid Antibody-Mediated Disease: Clinical Characteristics and Outcomes of Catastrophic Antiphospholipid Syndrome and Lupus Anticoagulant Hypoprothrombinemia in a Single Center Pediatric Cohort

Posters: Clinical and Therapeutic Aspects I

6:00PM-7:00PM: Abstract Number: 028

Are You Positive About this Positive ANA Referral? Outcomes for ANA Based Referrals to Pediatric Rheumatology and Subsequent Disease Development

Posters: Clinical and Therapeutic Aspects I

6:00PM-7:00PM: Abstract Number: 054

Assessing Completion of Healthcare Transition: A Retrospective Review of Provider Acknowledgment Following Pediatric Rheumatology Transfer

Posters: Quality, Health Services, and Education Research I

6:00PM-7:00PM: Abstract Number: 038

Assessment of Disease Activity and Skeletal Damage in Pediatric Chronic Nonbacterial Osteomyelitis and the Effects of Different Treatment Regimens

Posters: Clinical and Therapeutic Aspects I

6:00PM-7:00PM: Abstract Number: 047

Association of anti-DFS70 with autoimmune diseases in children

Posters: Clinical and Therapeutic Aspects I

6:00PM-7:00PM: Abstract Number: 008

Body Mass Index, Neighborhood Opportunity, and Outcomes of Childhood-Onset Lupus

Posters: Clinical and Therapeutic Aspects I

6:00PM-7:00PM: Abstract Number: 014

Bone Microarchitecture Impairment in Juvenile Systemic Lupus Erythematosus Patients: A Comparative Study

Posters: Clinical and Therapeutic Aspects I

6:00PM-7:00PM: Abstract Number: 020

Building Consensus on Key Research Domains and Research Topics in Childhood-onset Neuropsychiatric Lupus: An International Prioritization Initiative

Posters: Clinical and Therapeutic Aspects I

6:00PM-7:00PM: Abstract Number: 052

Case Series: Treatment of Refractory Lung Disease in Systemic Juvenile Idiopathic Arthritis with Cyclophosphamide and Rituximab Combination Therapy

Posters: Clinical and Therapeutic Aspects I

6:00PM-7:00PM: Abstract Number: 043

Challenges of Cognitive Screening and Formal Neuropsychological Evaluation in Youth with Childhood-Onset Systemic Lupus Erythematosus: A Survey of CARRA Providers

Posters: Clinical and Therapeutic Aspects I

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].